Skip to content

The Neuroregulation and Neurobiological Mechanism of Bright Light Therapy Combined with Mood Stabilizer on Bipolar Disorders

The Neuroregulation and Neurobiological Mechanism of Bright Light Therapy Combined with Mood Stabilizer on Bipolar Disorders

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066958
Enrollment
Unknown
Registered
2022-12-22
Start date
2023-01-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder

Interventions

BLT group in BD-DEP:BLT
sham BLT group in BD-DEP:sham BLT

Sponsors

Hangzhou Seventh People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 50 Years

Inclusion criteria

Inclusion criteria: (1) patients were received SCID-5-CV interview, meeting the DSM-5 criteria for BD (type I or type II). (2) 16-50 years of age. (3) had history of medication of Mood stabilizers (the list of firstly recommended mood stabilizers (such as lithium carbonate, valproate, or second-generation antipsychotics) at a therapeutic dose according to the Chinese Guidelines for the Prevention and Treatment of Bipolar Disorder (the second edition)) at least 2 weeks before recruited. (4) had a Hamilton Depression Scale (version: 17 Items; HAMD-17) total score=18. (5) Han nationality, right-handed, education of primary school, IQ>70, and ability of understanding the neuropsychological test. (6) volunteered to participate in this study and signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) a history of or current serious physical diseases, organic brain diseases, and nervous system diseases. (2) a history of or current other psychiatric disorders other than bipolar disorder, including neurodevelopmental disorders, schizophrenia or other psychiatric disorders, depressive disorders, anxiety disorders, abuse of or dependence on substances. (3) color blindness, color weakness affecting neurocognitive testing, or any contraindications for MRI. (4) IQ=70. (5) a history of or current retinodystrophy, age-related macular degeneration, porphyria, chronic actinic dermatitis, solar urticaria and other diseases. (6) for women, pregnancy, or planned pregnancy in recent three months. (7) had a history of other interventions such as electroconvulsive therapy and transcranial magnetic stimulation in recent 3 months. (8) inconsistent with or cannot effectively complete the treatment plan.

Design outcomes

Primary

MeasureTime frame
HAMD-17 score;brain blood oxygen level dependence;brain electrophysiological signals;Concentration information of neurotransmitters and metabolites;Genotyping;brain structure;Biorhythm;

Secondary

MeasureTime frame
cortisol;melatonin;

Countries

China

Contacts

Public ContactLi Tao

Hangzhou Seventh People’s Hospital

litaozjusc@zju.edu.cn+86 17826895253

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026